Altamira Therapeutics (CYTO) Corporate Presentation summary

Company overview and strategy

• Proprietary OligoPhore and Semaphore platforms enable efficient RNA delivery to extrahepatic tissues using peptide-based nanoparticles, addressing a key challenge in RNA therapeutics.

• Focus on partnering with pharma and biotech for platform out-licensing, with initial collaborations underway.

• Two flagship programs target KRAS-driven cancers (AM-401) and rheumatoid arthritis (AM-411), both aiming for IND filings in 2026.

• Legacy inner ear and OTC assets are being divested or partnered to unlock value and focus on RNA delivery.

Technology and differentiation

• OligoPhore/Semaphore nanoparticles deliver RNA safely and selectively to diseased tissues, avoiding liver sequestration and minimizing immune response.

• Demonstrated 10-fold higher endosomal escape compared to lipid nanoparticles, the current industry standard.

• Platforms are suitable for siRNA, mRNA, ASOs, and circular RNA, with in vivo proof in 17 disease models.

• Technology licensed exclusively from Washington University, with patent coverage until 2034 and potential extensions.

Market opportunity and growth

• RNA therapeutics market is rapidly expanding, with mRNA therapeutics projected to reach $101.3B and siRNA $11B by 2026.

• High unmet needs in oncology and inflammatory disorders, with few competing RNA projects for KRAS mutations and rheumatoid arthritis.

• Active M&A and licensing environment in the RNA space, with significant recent deals.